From CAR-T Cells to Exosome-Based Immunotherapy: Exploring the Frontiers of Cell-Free Targeted Cancer Therapeutics
Cells · 2025
DOI: 10.3390/cells15010070 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, 2025. Verfasst von Alexandru Tîrziu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Functional Sciences, "Victor Babes" University of Medicine and Pharmacy, Tudor Vladimirescu Street, No. 14, 300174 Timisoara, Romania. Hauptthemen laut MEDLINE: Exosomes, Neoplasms, Immunotherapy, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 288 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Planul Național de Redresare și Reziliență a României, RBC-engager for NK and T cell activation in cancer immunotherapy, “Victor Babes” University of Medicine and Pharmacy Timisoara.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR) cell therapies have revolutionized cancer immunotherapy by enabling targeted and potent antitumor immune responses. However, clinical challenges such as limited efficacy in solid tumors, severe toxicities including cytokine release syndrome (CRS), and manufacturing complexities restrict their broader use. Recently, CAR cell-derived exosomes (CAR-Exos) have emerged as promising cell-free therapeutic alternatives that retain the key antitumor functionalities of their parent cells while potentially overcoming the limitations of live cellular therapies. These nanoscale vesicles can deliver bioactive CAR molecules, cytotoxic proteins, and immunomodulatory cargo, enabling targeted tumor cell killing with reduced systemic toxicity and offering “off-the-shelf” applicability. This review comprehensively explores the biology, engineering, and therapeutic potential of CAR-Exos derived from T cells, natural killer (NK) cells, and other immune effectors. We discuss advances in isolation, characterization, and cargo profiling techniques, as well as preclinical and early clinical data supporting their application. Further, we address translational challenges including large-scale production, biodistribution, and immune evasion in tumor microenvironments. Combining cellular and exosomal CAR platforms holds promise to enhance efficacy and safety in cancer treatment, representing a frontier in targeted immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Functional Sciences, "Victor Babes" University of Medicine and Pharmacy, Tudor Vladimirescu Street, No. 14, 300174 Timisoara, Romania.
- Center for Gene and Cellular Therapies in the Treatment of Cancer Timisoara-OncoGen, Clinical Emergency County Hospital "Pius Brinzeu" Timisoara, No. 156 Liviu Rebreanu, 300723 Timisoara, Romania.
- Immuno-Physiology and Biotechnologies Center, Department of Functional Sciences, "Victor Babes" University of Medicine and Pharmacy, No. 2 Eftimie Murgu Square, 300041 Timisoara, Romania.
- Department of Orthopedics-Traumatology, Urology, and Medical Imaging, "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Square, No. 2, 300041 Timisoara, Romania.
ORCID-Profile: Florina Maria Bojin, Oana Isabella Gavriliuc, Cosmin Ioan Faur
Förderung
- Planul Național de Redresare și Reziliență a României
- RBC-engager for NK and T cell activation in cancer immunotherapy
- “Victor Babes” University of Medicine and Pharmacy Timisoara
Zitieren
APA
Tîrziu, A., Bojin, F. M., Gavriliuc, O. I., Faur, C. I., & Păunescu, V. (2025). From CAR-T Cells to Exosome-Based Immunotherapy: Exploring the Frontiers of Cell-Free Targeted Cancer Therapeutics. Cells. https://doi.org/10.3390/cells15010070
Vancouver
Tîrziu A, Bojin FM, Gavriliuc OI, Faur CI, Păunescu V. From CAR-T Cells to Exosome-Based Immunotherapy: Exploring the Frontiers of Cell-Free Targeted Cancer Therapeutics. Cells. 2025. doi:10.3390/cells15010070
BibTeX
@article{Trziu2025,
author = {Tîrziu, Alexandru and Bojin, Florina Maria and Gavriliuc, Oana Isabella and Faur, Cosmin Ioan and Păunescu, Virgil},
title = {From CAR-T Cells to Exosome-Based Immunotherapy: Exploring the Frontiers of Cell-Free Targeted Cancer Therapeutics},
journal = {Cells},
year = {2025},
doi = {10.3390/cells15010070}
}
EUVIMED